Serum levels of soluble programmed death-ligand 1 (sPD-L1): A possible biomarker in predicting post-treatment outcomes in patients with early hepatocellular carcinoma
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Serum levels of soluble programmed death-ligand 1 (sPD-L1): A possible biomarker in predicting post-treatment outcomes in patients with early hepatocellular carcinoma
Authors
Keywords
HCC, Ablation, Cirrhosis, PD-L1
Journal
INTERNATIONAL IMMUNOPHARMACOLOGY
Volume 94, Issue -, Pages 107467
Publisher
Elsevier BV
Online
2021-02-21
DOI
10.1016/j.intimp.2021.107467
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Elevated baseline serum PD-1 or PD-L1 predicts poor outcome of PD-1 inhibition therapy in metastatic melanoma
- (2020) S. Ugurel et al. ANNALS OF ONCOLOGY
- Prognostic value of programmed cell death ligand 1 (PD-L1) for hepatocellular carcinoma: a meta-analysis
- (2020) Xiao-Song Li et al. BIOSCIENCE REPORTS
- Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
- (2020) Richard S. Finn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liquid Biopsies in Hepatocellular Carcinoma: Are We Winning?
- (2020) Tudor Mocan et al. Journal of Clinical Medicine
- Prognostic role of PD-L1 for HCC patients after potentially curative resection: a meta-analysis
- (2019) Gao-Min Liu et al. Cancer Cell International
- Circulating levels of PD-L1 and Galectin-9 are associated with patient survival in surgically treated Hepatocellular Carcinoma independent of their intra-tumoral expression levels
- (2019) Kostandinos Sideras et al. Scientific Reports
- Plasma Levels of Soluble PD-L1 Correlate With Tumor Regression in Patients With Lung and Gastric Cancer Treated With Immune Checkpoint Inhibitors
- (2019) KIYOHIRO ANDO et al. ANTICANCER RESEARCH
- EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
- (2018) Peter R. Galle et al. JOURNAL OF HEPATOLOGY
- Hepatocellular carcinoma
- (2018) Alejandro Forner et al. LANCET
- Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
- (2018) Andrew X Zhu et al. LANCET ONCOLOGY
- Clinical significance of soluble programmed cell death ligand-1 (sPD-L1) in hepatocellular carcinoma patients treated with radiotherapy
- (2018) Hyun Ju Kim et al. RADIOTHERAPY AND ONCOLOGY
- Increased Expression of Programmed Death-Ligand 1 in Infiltrating Immune Cells in Hepatocellular Carcinoma Tissues after Sorafenib Treatment
- (2018) Li-Chun Lu et al. Liver Cancer
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Pre-treatment serum levels of soluble programmed cell death-ligand 1 predict prognosis in patients with hepatitis B-related hepatocellular carcinoma
- (2018) Xue Han et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- The correlation and prognostic value of serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death-ligand 1 (sPD-L1) in patients with hepatocellular carcinoma
- (2018) Boyang Chang et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Programmed cell death protein-1 (PD-1)/programmed death-ligand-1 (PD-L1) axis in hepatocellular carcinoma: prognostic and therapeutic perspectives
- (2018) T. Mocan et al. Clinical & Translational Oncology
- Prognostic factors after percutaneous radiofrequency ablation in the treatment of hepatocellularcarcinoma. Impact of incomplete ablation on recurrence and overall survival rates
- (2018) Journal of Gastrointestinal and Liver Diseases
- Increase of Soluble Programmed Cell Death Ligand 1 in Patients with Chronic Hepatitis C
- (2017) Satoshi Yamagiwa et al. International Journal of Medical Sciences
- Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
- (2017) Anthony B El-Khoueiry et al. LANCET
- High plasma levels of soluble programmed cell death ligand 1 are prognostic for reduced survival in advanced lung cancer
- (2017) Yusuke Okuma et al. LUNG CANCER
- Prognostic significance of PD-L1 in solid tumor
- (2017) Qianqian Wang et al. MEDICINE
- Serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death ligand 1 (sPD-L1) in advanced pancreatic cancer
- (2017) Stephan Kruger et al. OncoImmunology
- High levels of the soluble programmed death-ligand (sPD-L1) identify hepatocellular carcinoma patients with a poor prognosis
- (2016) Fabian Finkelmeier et al. EUROPEAN JOURNAL OF CANCER
- Programmed death ligand 1 expression in hepatocellular carcinoma: Relationship With clinical and pathological features
- (2016) Julien Calderaro et al. HEPATOLOGY
- PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations
- (2016) Weiping Zou et al. Science Translational Medicine
- Intratumor Heterogeneity in Hepatocellular Carcinoma
- (2014) J. Friemel et al. CLINICAL CANCER RESEARCH
- High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial
- (2014) D Rossille et al. LEUKEMIA
- PD-L1 Expression in the Merkel Cell Carcinoma Microenvironment: Association with Inflammation, Merkel Cell Polyomavirus, and Overall Survival
- (2013) E. J. Lipson et al. Cancer Immunology Research
- Overexpression of PD-L1 Significantly Associates with Tumor Aggressiveness and Postoperative Recurrence in Human Hepatocellular Carcinoma
- (2009) Q. Gao et al. CLINICAL CANCER RESEARCH
- Prognostic value of pretreatment levels of tumor markers for hepatocellular carcinoma on survival after curative treatment of patients with HCC
- (2008) Hidenori Toyoda et al. JOURNAL OF HEPATOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now